132 related articles for article (PubMed ID: 8215248)
1. The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain.
Hammerstad JP; Pate BD; Hewitt KA; Chan GL; Ruth TJ; Calne DB
Ann Neurol; 1993 Oct; 34(4):603-8. PubMed ID: 8215248
[TBL] [Abstract][Full Text] [Related]
2. 3-O-methyldopa administration does not alter fluorodopa transport into the brain.
Guttman M; Léger G; Cedarbaum JM; Reches A; Woodward W; Evans A; Diksic M; Gjedde A
Ann Neurol; 1992 Jun; 31(6):638-43. PubMed ID: 1514775
[TBL] [Abstract][Full Text] [Related]
3. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
[TBL] [Abstract][Full Text] [Related]
4. Postinjection L-phenylalanine increases basal ganglia contrast in PET scans of 6-18F-DOPA.
Doudet DJ; McLellan CA; Aigner TG; Wyatt R; Adams HR; Miyake H; Finn RT; Cohen RM
J Nucl Med; 1991 Jul; 32(7):1408-13. PubMed ID: 1906094
[TBL] [Abstract][Full Text] [Related]
5. Metabolites of 6-[18F]fluoro-L-dopa in human blood.
Firnau G; Sood S; Chirakal R; Nahmias C; Garnett ES
J Nucl Med; 1988 Mar; 29(3):363-9. PubMed ID: 3126278
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.
Leenders KL; Poewe WH; Palmer AJ; Brenton DP; Frackowiak RS
Ann Neurol; 1986 Aug; 20(2):258-62. PubMed ID: 3092728
[TBL] [Abstract][Full Text] [Related]
7. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-dopa uptake in brain.
Doudet DJ; McLellan CA; Aigner TG; Wyatt RJ; Cohen RM
J Nucl Med; 1992 Jul; 33(7):1383-9. PubMed ID: 1613582
[TBL] [Abstract][Full Text] [Related]
8. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
[TBL] [Abstract][Full Text] [Related]
9. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates.
Pate BD; Snow BJ; Hewitt KA; Morrison KS; Ruth TJ; Calne DB
J Nucl Med; 1991 Jun; 32(6):1246-51. PubMed ID: 1904482
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat.
Cumming P; Ase A; Diksic M; Harrison J; Jolly D; Kuwabara H; Laliberté C; Gjedde A
Biochem Pharmacol; 1995 Sep; 50(7):943-6. PubMed ID: 7575677
[TBL] [Abstract][Full Text] [Related]
11. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
12. The influx of neutral amino acids into the porcine brain during development: a positron emission tomography study.
Brust P; Vorwieger G; Walter B; Füchtner F; Stark H; Kuwabara H; Herzau M; Opfermann T; Steinbach J; Ganapathy V; Bauer R
Brain Res Dev Brain Res; 2004 Sep; 152(2):241-53. PubMed ID: 15351512
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat.
Cumming P; Häusser M; Martin WR; Grierson J; Adam MJ; Ruth TJ; McGeer EG
Biochem Pharmacol; 1988 Jan; 37(2):247-50. PubMed ID: 3124856
[TBL] [Abstract][Full Text] [Related]
14. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.
Melega WP; Grafton ST; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
J Cereb Blood Flow Metab; 1991 Nov; 11(6):890-7. PubMed ID: 1939384
[TBL] [Abstract][Full Text] [Related]
15. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
Melega WP; Luxen A; Perlmutter MM; Nissenson CH; Phelps ME; Barrio JR
Biochem Pharmacol; 1990 Jun; 39(12):1853-60. PubMed ID: 2112915
[TBL] [Abstract][Full Text] [Related]
17. Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA.
Yee RE; Cheng DW; Huang SC; Namavari M; Satyamurthy N; Barrio JR
Biochem Pharmacol; 2001 Nov; 62(10):1409-15. PubMed ID: 11709201
[TBL] [Abstract][Full Text] [Related]
18. 6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography.
Melega WP; Hoffman JM; Schneider JS; Phelps ME; Barrio JR
Brain Res; 1991 Mar; 543(2):271-6. PubMed ID: 1905578
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA.
DeJesus OT; Endres CJ; Shelton SE; Nickles RJ; Holden JE
J Nucl Med; 1997 Apr; 38(4):630-6. PubMed ID: 9098215
[TBL] [Abstract][Full Text] [Related]
20. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
